Protein Design Labs signs patent rights deal with AHP
US firm Protein Design Labs has entered into a two-year patent rightsagreement with American Home Products, under which the latter will pay a non-refundable, non-creditable upfront (undisclosed) fee to PDL for the rights to obtain a worldwide, non-exclusive license under its antibody humanization patents for antibodies to a specific (unidentified) target antigen.
Upon exercise of the rights, AHP will pay an additional fee to PDL and possibly license maintenance fees and royalties on sales of the antibodies. AHP currently has a non-exclusive worldwide license to market the PDL-developed anticancer drug Mylotarg (gemtuzumab ozogamicin for injection), which gained US regulatory approval last May (Marketletter May 29, 2000).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze